title: Tolerance of adjuvant letrozole outside of clinical trials.
abstract: Recently aromatase inhibitors have become a standard care as an adjuvant treatment for many postmenopausal patients with hormone receptor positive early breast cancer. Adjuvant letrozole was made available either immediately postoperative, after 2-3 years of tamoxifen, or as an extended treatment after 5 years of tamoxifen. Between October 2003 and October 2005, we analyzed the subjective tolerance in 185 postoperative early breast cancer patients receiving letrozole outside of a clinical trial. The most prominent toxicity was musculoskeletal pain. In addition hot flushes, increased fatigue, nausea, vomiting, anorexia, mood disturbances, vaginal dryness, hair loss and rash were also recorded. In contrast to the prospective randomized clinical trials, a high drop-out rate of 20% was documented, mainly due to aromatase inhibitor-associated arthralgia syndrome interfering significantly with the daily life of our patients. Although adjuvant aromatase inhibitors have proven to be generally superior to tamoxifen in the adjuvant setting, it is important to focus attention on the tolerance during the adjuvant therapy and to balance this against the potential benefit in individual patients. Alternative options including switching to tamoxifen remain available.
authors.affiliation: Department of Medical Oncology, Oncologisch Centrum, UZ Brussel, Vrije Universiteit Brussel, Laarbeeklaan 101, B-1090 Jette, Belgium.
authors.forename: C
authors.initials: C
authors.lastname: Fontaine
authors.forename: A
authors.initials: A
authors.lastname: Meulemans
authors.forename: M
authors.initials: M
authors.lastname: Huizing
authors.forename: C
authors.initials: C
authors.lastname: Collen
authors.forename: L
authors.initials: L
authors.lastname: Kaufman
authors.forename: J
authors.initials: J
authors.lastname: De Mey
authors.forename: C
authors.initials: C
authors.lastname: Bourgain
authors.forename: G
authors.initials: G
authors.lastname: Verfaillie
authors.forename: J
authors.initials: J
authors.lastname: Lamote
authors.forename: R
authors.initials: R
authors.lastname: Sacre
authors.forename: D
authors.initials: D
authors.lastname: Schallier
authors.forename: B
authors.initials: B
authors.lastname: Neyns
authors.forename: J
authors.initials: J
authors.lastname: Vermorken
authors.forename: J
authors.initials: J
authors.lastname: De Grève
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D047072:Aromatase Inhibitors / Q000009:adverse effects*; D018771:Arthralgia / Q000139:chemically induced; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D015331:Cohort Studies; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D000077289:Letrozole; D008408:Mastectomy; D008875:Middle Aged; D009570:Nitriles / Q000009:adverse effects*; D017698:Postmenopause; D012189:Retrospective Studies; D014230:Triazoles / Q000009:adverse effects*
chemical_list: D000970:Antineoplastic Agents; D047072:Aromatase Inhibitors; D009570:Nitriles; D014230:Triazoles; D000077289:Letrozole